

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4564890

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CHANGE OF NAME
CONVEYING PARTY DATA	
Name	Execution Date
CYTOCORE, INC.	11/20/2014
RECEIVING PARTY DATA	
Name:	MEDITE CANCER DIAGNOSTICS, INC.
Street Address:	4203 SW 34TH STREET
City:	ORLANDO
State/Country:	FLORIDA
Postal Code:	32811
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	14774988
Patent Number:	9463137
CORRESPONDENCE DATA	
Fax Number:	(317)713-3699
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	317-713-3455
Email:	rwhite@taftlaw.com
Correspondent Name:	RYAN O. WHITE
Address Line 1:	ONE INDIANA SQUARE
Address Line 2:	SUITE 3500
Address Line 4:	INDIANAPOLIS, INDIANA 46204
ATTORNEY DOCKET NUMBER:	MCD11-GN001
NAME OF SUBMITTER:	RYAN O. WHITE
SIGNATURE:	/Ryan O. White/
DATE SIGNED:	08/24/2017
Total Attachments: 1	
source=MEDITE CANCER DIAGNOSTICS INC - DE - Certified Copy#page1.tif	

CERTIFICATE OF AMENDMENT
TO THE
CERTIFICATE OF INCORPORATION
OF
CYTOCORE, INC.

Pursuant to Section 242 of the
General Corporation Law of the State of Delaware

CytoCore, Inc., a Delaware corporation (the "Corporation"), does hereby certify as follows:

1. The Board of Directors of the Corporation (the "Board"), acting by Unanimous Written Consent in accordance with Section 141(f) of the General Corporation Law of the State of Delaware (the "DGCL") adopted a resolution authorizing the following amendment (the "Amendment") to the Corporation's Articles of Incorporation:

Article FIRST of the Certificate of Incorporation of the Corporation shall be amended by deleting such Article FIRST thereof in its entirety and substituting therefor the following:

"FIRST: The name of the Corporation is Medite Cancer Diagnostics, Inc.

2. This Amendment shall take effective at 5:00 p.m. on December 1, 2014.

3. That the aforesaid amendment was duly adopted in accordance with the applicable provisions of Section 242 of the DGCL.

IN WITNESS WHEREOF, CytoCore, Inc. has caused this Certificate of Amendment to be duly executed in its corporate name this 20th day of November, 2014.

CYTOCORE, INC.

By: 
Michaela Ott, Chief Executive Officer